Breaking
•Ohio starts removing 200-foot dam after 80 years to restore 14-mile creek•Small trial finds ear device for high BP safe and easy to use at home•Pakistan wins toss, elects to field against England in tri-series ODI - Yahoo News New Zealand•Pakistan axe Shan Masood from Sri Lanka Test squad as Agha, Rizwan return•Premier League live updates: Man United face Bournemouth, Liverpool host Brighton - ESPN•Updated SEC football conference standings following Week 8 upsets - Yahoo Sports•Where Commanders QB Jayden Daniels Shines, But Must Go Next - Yahoo Sports•The Rays Are Down, But Not Out, As The World Series Heads To Tampa Bay - FOX Sports•Whose vision of development counts? South Africa’s Amadiba communities made maps of what matters - Modern Ghana•Award honours academic driving South Africa’s green transition - ednews.africa•Serbia goes to polls to choose between Vučić and student movement - Euronews.com•Kazakhstan’s next chapter: turning national wealth into a national dividend - EU Reporter•Why I Chose to Stop Traveling to Europe, and Why You Might Too - Yahoo•Days before Israeli election, military conducts massive West Bank operation - News4JAX•Former Keralam Governor Arlekar recommends President to remove PSC chairperson; Opposition LDF calls move unconstitutional•Congress demands Manipur CM’s resignation, fresh polls amid renewed violence•German billionaire says €250mn Bayern Munich deal about more than money•Audi to build $4bn US plant as it grapples with tariffs•Airbus to hold talks with BAE over role in GCAP fighter jet programme•Breaking: An Se-young Wins French Open, Extends Winning Streak to 50 - 조선일보•Ohio starts removing 200-foot dam after 80 years to restore 14-mile creek•Small trial finds ear device for high BP safe and easy to use at home•Pakistan wins toss, elects to field against England in tri-series ODI - Yahoo News New Zealand•Pakistan axe Shan Masood from Sri Lanka Test squad as Agha, Rizwan return•Premier League live updates: Man United face Bournemouth, Liverpool host Brighton - ESPN•Updated SEC football conference standings following Week 8 upsets - Yahoo Sports•Where Commanders QB Jayden Daniels Shines, But Must Go Next - Yahoo Sports•The Rays Are Down, But Not Out, As The World Series Heads To Tampa Bay - FOX Sports•Whose vision of development counts? South Africa’s Amadiba communities made maps of what matters - Modern Ghana•Award honours academic driving South Africa’s green transition - ednews.africa•Serbia goes to polls to choose between Vučić and student movement - Euronews.com•Kazakhstan’s next chapter: turning national wealth into a national dividend - EU Reporter•Why I Chose to Stop Traveling to Europe, and Why You Might Too - Yahoo•Days before Israeli election, military conducts massive West Bank operation - News4JAX•Former Keralam Governor Arlekar recommends President to remove PSC chairperson; Opposition LDF calls move unconstitutional•Congress demands Manipur CM’s resignation, fresh polls amid renewed violence•German billionaire says €250mn Bayern Munich deal about more than money•Audi to build $4bn US plant as it grapples with tariffs•Airbus to hold talks with BAE over role in GCAP fighter jet programme•Breaking: An Se-young Wins French Open, Extends Winning Streak to 50 - 조선일보
TheNewsPulse.pro
Home/clinical trials/diseases/drugs
clinical_trials

Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial

Confidence95·multiple reportsImportance97NP-EVT-20261024-D81F454

Nature Medicine, Published online: 24 October 2026; doi:10.1038/s41591-026-04740-9 As presented at the ESMO Congress 2026: In this exploratory, nonrandomized phase 2a trial, treatment of patients with immune checkpoint inhibitor-naive muscle-invasive bladder cancer with the GDF-15-neutralizing antibody visugromab and nivolumab produced encouraging pathological complete response and radiographic response rates with no new safety signals, supporting further evaluation in larger randomized studie

Read the original at the primary source
Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial
Felix S. Lichtenegger · 10/24/2026, 12:00:00 AM
Also on the network: airlinesairports · farmerspulse · foodpulse · indianhealthpulse · indias · keralahealth · naturepulse · travelerpulse

Discussion

ChatsPulse · 0 threads

No discussion yet. Sign in and start the first thread —